Video Experimental Relacionado

Updated: Dec 15, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Asociación del Factor V Leiden con sucesos aterocrombóticos: un estudio GENIUS-CHD de datos de participantes

Bakhtawar K Mahmoodi^1,2, Vinicius Tragante³, Marcus E Kleber⁴

¹St. Antonius Hospital, Department of Cardiology, Nieuwegein, the Netherlands (B.K.M., T.O.B., J.M.t.B.).

|July 14, 2020

Resumen

Factor V Leiden no aumenta el riesgo de eventos aterotrombóticos en pacientes con enfermedad coronaria (CHD). Las pruebas genéticas de rutina para este factor no se recomiendan para la estratificación del riesgo en esta población.

Área de la Ciencia:

Genética cardiovascular
Trombosis y hemostasis
Epidemiología

Sus antecedentes:

Existen estudios limitados sobre el papel del Factor V Leiden en pacientes con enfermedad coronaria establecida (CHD).
Los factores de coagulación, incluido el Factor V Leiden, pueden influir en la formación de trombos en las placas ateroscleróticas.
Hipótesis: El Factor V Leiden es un factor de riesgo significativo para eventos atero- trombóticos en pacientes con ECC.

Objetivo del estudio:

Investigar la asociación entre el Factor V Leiden y los eventos aterotrombóticos en pacientes con ECC establecida.
Determinar si el factor V Leiden puede mejorar la estratificación del riesgo de eventos cardiovasculares en este grupo de alto riesgo.

Principales métodos:

Metaanálisis a nivel individual de 25 estudios prospectivos (consorcio GENIUS-CHD).
Se incluyeron 69.681 participantes con enfermedad coronaria establecida, evaluando el estado del Factor V Leiden.
Regresión de Cox y metaanálisis de efecto fijo utilizados para evaluar los resultados primarios (IM, muerte por ECC) y secundarios.

Principales resultados:

El factor V Leiden no se asoció con un aumento del riesgo de infarto de miocardio o muerte por enfermedad coronaria (HR 1, 03, IC del 95% 0, 92-1, 16).
No se observaron diferencias significativas en los análisis de subgrupos basados en factores de riesgo cardiovascular.
Los resultados secundarios, incluidos el accidente cerebrovascular y la mortalidad, tampoco mostraron asociación con el Factor V Leiden.

Conclusiones:

El Factor V Leiden no aumenta el riesgo de sucesos aterotrombóticos posteriores ni la mortalidad en pacientes con enfermedad coronaria establecida.
Es poco probable que la evaluación rutinaria del Factor V Leiden mejore la estratificación del riesgo atero- trombótico en esta población.

Palabras clave:

Enfermedad arterial coronaria Estudios de asociación genética Infarto de miocardio el pronóstico Prevención secundaria de la enfermedad polimorfismo de un solo nucleótido Trombosis

Más Videos Relacionados

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Videos de Conceptos Relacionados

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Acute Coronary Syndrome III: Diagnostic Studies

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...